Total Utang marang Modal GT Biopharma Corp (GTBP)

The market trend for the total debt-to-equity ratio of GT Biopharma, Inc. (GTBP) stands at 0.00. The firm's financial position relies on clinical test results and external contracts, as there is currently no operating income. Growth potential is based on the TriKE platform, which effectively directs immune cells against leukemias, while the environmental footprint remains minimal due to a virtual drug development format.

gtbiopharma.com (GTBP): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 31.10.2026

Rincian metrik lan analitis perusahaan GT Biopharma Corporation (GTBP)

- rega saham lan konsensus proyeksi valuasi:

Rega saham GT Biopharma|GTBP - Target konsensus

- rincian kapitalisasi pasar:

Kapitalisasi pasar GT Biopharma|GTBP - Nilai Perusahaan

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham GT Biopharma|GTBP - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku gtbiopharma.com|GTBP - Gunggung Aset Perusahaan

- rincian utang lan likuiditas:

- data bathi resik lan rasio valuasi:

GTBP - Bathi resik perusahaan

Pambiji fundamental perusahaan:GT Biopharma

For the small biotech company GT Biopharma, Inc. (GTBP), which faces a high burn rate and regulatory risks, controlling the financing structure is critical. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed funds relative to equity, where a downward trend confirms a reduction in debt load, while an increase indicates dangerous financial leverage that limits business resilience.

Analisis pesaing GT Biopharma, Inc.

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Syndax Corp (SNDX)|Utang marang Ekuitas Kura Oncology, Inc. KURA|ADCT: Rasio Utang marang Ekuitas|Foghorn - Total Utang marang Modal|Vor Biopharma, Inc. (VOR) - Rasio Total Utang marang Ekuitas|NKTX: Total Utang marang Modal|Utang marang Modal Coeptis Therapeutics, Inc. (COEP)|Utang marang Ekuitas Actinium Pharmaceuticals|ESLA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal INAB (IN8bio, Inc)|Eterna Therapeutics, Inc. - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)